Advisory Services Network Lowers stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Advisory Services Network reduced its stake in Celgene Corporation by 0.5% during the most recent quarter end. The investment management company now holds a total of 37,244 shares of Celgene Corporation which is valued at $4,116,207 after selling 189 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Celgene Corporation makes up approximately 1.11% of Advisory Services Network’s portfolio.

Celgene Corporation closed down -1.4 points or -1.30% at $106.15 with 59,08,642 shares getting traded on Wednesday. Post opening the session at $107.9, the shares hit an intraday low of $105.82 and an intraday high of $108.11 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Sit Investment Associates Inc reduced its stake in CELG by selling 6,925 shares or 6.0% in the most recent quarter. The Hedge Fund company now holds 108,520 shares of CELG which is valued at $11,648,537. Celgene Corporation makes up approx 0.21% of Sit Investment Associates Inc’s portfolio.Neville Rodie Shaw Inc reduced its stake in CELG by selling 1,450 shares or 1.62% in the most recent quarter. The Hedge Fund company now holds 87,781 shares of CELG which is valued at $9,422,413. Celgene Corporation makes up approx 1.13% of Neville Rodie Shaw Inc’s portfolio.Jacobs Coca reduced its stake in CELG by selling 65 shares or 0.37% in the most recent quarter. The Hedge Fund company now holds 17,522 shares of CELG which is valued at $1,880,811. Celgene Corporation makes up approx 0.45% of Jacobs Coca’s portfolio.Oakwood Capital Managementca boosted its stake in CELG in the latest quarter, The investment management firm added 2,030 additional shares and now holds a total of 48,051 shares of Celgene Corporation which is valued at $5,157,794. Celgene Corporation makes up approx 1.35% of Oakwood Capital Managementca’s portfolio.

On the company’s financial health, Celgene Corporation reported $1.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus of $1.21. The company had revenue of $2563.30 million for the quarter, compared to analysts expectations of $2548.22 million. The company’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 135 from a previous price target of $150 .

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.